Rénibus Therapeutics® Inc.
is a biotech company dedicated to transforming the cardio-renal disease treatment paradigm by focusing on the prevention and treatment of kidney disease. Each year, 9 million U.S. adults suffer from acute kidney injury (AKI), and today, 37 million U.S. adults are living with chronic kidney disease (CKD). As the most common complication of a number of surgical procedures, AKI occurs in approximately 30% of patients undergoing cardiac surgery. It is associated with a higher risk of mortality in both inpatient and outpatient settings, and progression to CKD within 24 months occurs in approximately 15-20% of patients who survive AKI. The quality of life and financial burdens of AKI and CKD have reached insurmountable proportions for patients and their families. Unfortunately, there are currently no approved therapies for prevention or treatment of AKI or to stop the progression of CKD leading to dialysis.
Rénibus’ RTI’s lead product, RBT-1, is a novel pharmacologic intervention that induces preconditioning of the kidney, upregulating production of protective proteins to prevent AKI during cardiac surgery. Phase I development is completed, and a RBT-1’s first Phase II trial initiated in April 2021 and is expected to be completed in Q2 2022; a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing Coronary Artery Bypass Graft (CABG) and/or Cardiac Valve Surgery (The START Study). RBT-2 (tetrahydrodiferuloylmethane) is an active metabolite of an antioxidant natural product that reduces CKD progression by restoring cellular homeostasis and reducing inflammation and fibrosis development. Protective effects of RBT-2 have also been observed in the heart. RBT-2: formulation and IND enabling work in progress. Phase I study expected to start in Q4 2022. RBT-3 rapidly increases plasma ferritin without inducing nephrotoxicity or cardiotoxicty. Phase III development with RBT-3 is expected to be in 2H, 2022.
Executive Management Team
Board of Directors
Laboratory of Basic and Translational Research
Acute Kidney Injury (AKI)
Recognizing the need to improve treatment and health outcomes for patients with kidney disease, an Executive Order on Advancing American Kidney Health was issued in 2019 by the President of the United States. This initiative set forth policy with “a focus on delaying or preventing the onset of kidney failure, preventing unnecessary hospitalizations, and increasing the rate of transplants.” Preventing or reducing the severity of AKI is a critical step toward achieving these goals, especially as no such treatments are currently available. This unmet medical need is also highlighted by the fact that 15-20% of patients with AKI develop chronic kidney disease (CKD). Despite approximately 30 million adults in the US with CKD, there are no approved treatments to stop progression of this disease.
- 20% of all hospitalized patients in developed countries develop AKI; this rate increases to 67% in the ICU setting
- AKI severity is associated with a higher risk of mortality in both inpatient and outpatient settings
- Annual death rate from AKI in the US is higher than breast cancer, lung cancer, diabetes, and heart failure combined
- AKI confers a 9 times higher risk of CKD
- AKI confers a 2 times higher risk of premature death
- AKI contributes to incident CKD and accelerated progression of end-stage renal disease (ESRD)
- Annual cost of AKI in the US is approximately $10 billion, representing a large economic health burden
- One of the most expensive conditions in US hospitals, with a cost of ~$5 billion for 498,000 hospital stays in 2011
- Most common complication of a number of surgical procedures, including coronary artery bypass grafting
Chronic Kidney Disease (CKD)
- 30 million people or approximately 15% of U.S. Adults have CKD. (CDC 2017)
- Almost one out of every 7 adults 30-64 years of age is expected to develop CKD during their lifetime
- While dialysis-dependent CKD accounts for only 0.5% of the U.S. population, fee-for-service expenditures for Medicare beneficiaries with dialysis-dependent CKD exceeded 30 billion dollars in 2013, or over 7% of the Medicare paid claims cost
- Escalation in healthcare expenditures associated with CKD starts prior to the requirement for dialysis and treatment cost escalate as non-dialysis dependent CKD progresses
- CKD is a significant unmet medical need, and the financial burden has reached insurmountable proportions for patients and the U.S. healthcare system. In 2018, Medicare costs were $119 billion, and similar public cost burdens likely exist in the EU and Asia.
RBT-1: Iron Sucrose (FeS) and
Stannus Protoporphyrin (SnPP)
RBT-1 is a newly developed combination product designed to induce preconditioning of the kidney, upregulating production of protective proteins to prevent AKI during cardiac surgery.
Preclinical: Complete. Conditioning Rx protects against AKI, hepatic injury, and cardiac injury in response to AKI in animal models.
RBT-1’s first Phase II trial initiated in April 2021 and is expected to be completed in Q2 2022.
RBT-2 (tetrahydrodiferuloylmethane) is an active metabolite of an antioxidant natural product that reduces CKD progression by restoring cellular homeostasis and reducing inflammation and fibrosis development. Protective effects of RBT-2 have also been observed in the heart. RBT-2: formulation and IND enabling work in progress. Phase I study expected to start in Q4 2022.
RBT-3 is being developed to treat iron deficiency anemia. RBT-3 rapidly increases plasma ferritin without inducing nephrotoxicity or cardiotoxicity. Phase III development with RBT-3 is expected to begin in 2H, 2022.